Disease |
Disease |
Method |
Sample |
Expression pattern |
Dysfunction type |
Description |
PMID |
Source |
multiple myeloma |
methylation-specific PCR etc. |
cell lines (KMS-12-PE, LP-1, NCI-H929, OPM-2, OCI-MY5) |
differential expression |
expression |
Herein, by methylation-specific PCR, the putative KIAA0495 promoter was found unmethylated in all healthy controls (N = 14) but methylated in 50 % of myeloma cell lines (N = 10). KIAA0495 methylation was shown inversely correlated with KIAA0495 expression. However, KIAA0495 methylation was detected in none of both primary myeloma samples at diagnosis (N = 61) and at relapse/progression (N = 16). Collectively, despite frequently methylated in cell lines, KIAA0495 methylation appeared unimportant in the pathogenesis or progression of myeloma. |
26410378 |
Lnc2Cancer
|
esophageal squamous cell carcinoma |
microarray, knockdown |
esophageal squamous cell carcinoma, mouse xenografts |
up-regulated |
interaction |
In mouse xenografts, tumor size was reduced in lncRNA TP73-ASI siRNA-transfected tumors, suggesting that downregulation of lncRNA TP73-AS1 attenuated EC proliferation in vitro and in vivo. lncRNA TP73-AS1 knockdown enhanced the chemosensitivity of esophageal cancer cells to 5-FU and cisplatin. |
26799587 |
|
non-small cell lung cancer |
microarray, qPCR etc. |
NSCLC tissue |
down-regulated |
expression |
Furthermore, the levels of LINC00261 and TP73-AS1 were significantly differently expressed in subgroups of NSCLC samples (P = 0.004 and P = 0.03, respetcively). These lncRNAs could be further exploited for the development of useful biomarkers in diagnosis, prognosis and treatment of NSCLC. |
25590602 |
Lnc2Cancer
|
|